Background/Aims: Although there have been a few reports regarding the effect of basal
INTRODUCTION
Hepatitis B virus (HBV) has a 3.2 kb circular DNA genome containing four partially overlapping open reading frames (ORFs): C, encoding the nucleocapsid (core) protein (HBcAg) and secreted e antigen (HBeAg); P, the polymerase protein (Pol); S, the envelope proteins; and X, a transcriptional trans-activator protein. The core promoter located at nucleotides (nt) 1591-1822 plays a central role in virus replication, directing the synthesis of the pregenomic RNA, which, as well as being the template for genome synthesis, encodes HBcAg and Pol, and the precore RNA, which encodes HBeAg [1] .
The basal core promoter (BCP) has been mapped to nt 1744 to 1804 [2] .
The lack of proof-reading during reverse transcription of the pregenomic RNA favours the development of sequence variants during long-term HBV replication [3] . One of the most critical changes is the appearance of double mutations at nt 1762 (A to T) and 1764 (G to A) in the BCP. The mutations were first reported by Okamoto et al. who suggested that they might arrest the transcription of the precore RNA but not seriously affect that of the pregenomic RNA [4] . However, others suggested that these mutations seem to be insufficient to generate an HBeAg-negative phenotype [5] but may suppress the expression of HBeAg [6] . Subsequently, studies involving transfection of human hepatoma cell lines and analysis of clinical samples showed that these double mutations suppress, but do not abolish, the synthesis of HBeAg and may also and increase HBV DNA replication [2, 7, 8] .
However, other reports do not support the conclusion that BCP double mutations increase virus replication, in that the BCP double mutations seem to have no effect on viral load [9] [10] [11] [12] or even may be associated with lower serum HBV DNA concentrations [13] .
Furthermore, others found in transfection studies that core promoter mutations other than those at nt 1762/1764 seem to upregulate viral DNA replication [14, 15] . Therefore, the effect of the BCP double mutations on viral loads remains uncertain.
HBeAg has been used as a marker of infectivity and active virus replication in HBsAgpositive individuals [16, 17] . Seroconversion from HBeAg to anti-HBe, either spontaneous or after antiviral therapy, usually results in lower viral loads, this decline occurring usually up to twelve months before seroconversion [18] . Furthermore, because of the complexity of the host immune system, viral loads may fluctuate over time [19] .
Therefore, a single measurement, or several measurements made around the time of clearance of HBeAg, may not give a clear view of the effect of BCP double mutations on viral loads. In this study, taking the advantage of our Chinese cohort [20] , we have carried out a cross-sectional analysis to determine the association of BCP double mutations and viral loads and a 3 year-longitudinal analysis to test this association further.
STUDY SUBJECTS AND METHODS

The Long An cohort
In order to determine the value of screening carriers of hepatitis B surface antigen townships of Long An county to visit agricultural workers aged 30-55 for a 3 ml sample of blood by venepuncture for screening for HBsAg. All samples were tested for HBsAg and those positive were tested in China for HBV DNA using nested PCR. We also detected and excluded those positive for anti-HCV or alpha-fetoprotein (AFP) to eliminate the confounding effect of HCV infection on the incidence of HCC and preexisting HCC. We started to follow up our study subjects from 1st July, 2004. Each study subject completed a one-page questionnaire at the first visit and provided a serum sample every six months for the assessment of virological parameters and AFP concentrations and was monitored for HCC by ultrasonography (US).
Study subjects
Cross-sectional analysis and POLSEQ2 (nt1168-1188,5'-AGCAAACACTTGGCATAGGC-3') and the same amplification protocol as first round.
Products from the second rounds were confirmed by agarose gel electrophoresis and then purified using the GenElute TM PCR Clean-up Kit (SIGMA, St. Louis MO, USA)
according to the manufacturer's instructions. Cycle sequencing was carried out directly on both strands using 2 μl purified amplicon DNA and primer LSBI1 or ADELN (nt 432-453, 5'-TAGTCCAGAAGAACCAACAAG-3') and a BigDye® Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions.
Measurement of Viral loads
Viral load measurements were carried out as described by Garson et al. [22] . Briefly, HBV DNA was extracted from serum samples using a Qiagen BioRobot 9604 and QIAamp96 Virus Kit reagents (Qiagen, Hilden, Germany). Viral DNA was amplified and quantified in an ABI Prism 7000 sequence detection system (Applied Biosystems, Foster
City, CA, USA) using HBV primers and a dual labelled TaqMan probe as described.
HBV Genotyping
HBV genotyping were determined using HBV S gene sequences above and the programmes STAR (http://www.vgb.ucl.ac.uk/starn.shtml [23] and the NCBI Genotyping Tool (http://www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi).
Statistical Methods
For all analyses, a logarithmic transformation was applied to all viral load measurements prior to analysis to achieve an approximately normal distribution.
Cross-sectional analysis
Unadjusted comparisons between those with and without the BCP mutations were performed using unpaired t-tests on the logged values; multiple linear regression analysis was then used to assess whether any differences remained significant after adjusting for HBeAg status and other factors (age, sex and HBV genotype). Formal tests of interaction were performed to determine whether any associations noted differed quantitatively or qualitatively between those who were HBeAg negative and those who were HBeAg positive.
Longitudinal analysis
In the longitudinal analyses, viral loads at 12, 24 and 36 months, and pre-and postHBeAg seroconversion were summarised using medians and ranges; logged viral loads were then compared in those with and without the double mutations at each timepoint using unpaired t-tests. For the group who experienced HBeAg seroconversion, assessment of the significance of changes in viral load from pre-to post-seroconversion, overall and within each subgroup, was performed using a Signed ranks test as the changes, even after logarithmic transformation, were not Normally distributed.
All P-values were two-tailed, and P <0.05 was considered to be significant.
RESULTS
Cross-sectional analysis of the association of BCP double mutations and viral loads
Baseline viral loads in the various subgroups are shown in Table 1 Table 2 ), but the apparent associations with triple mutations (nt 1753, 1762 and 1764) and mutations between nt 1809-1817 became non-significant. Table 3 and Fig. 1 ).
Association of BCP double mutations and viral loads before and after HBeAg seroconversion in individuals without evolution of the BCP
Seventeen individuals (11 with BCP double mutations, 6 with wild type BCP)
contributed to the analysis of changes in viral loads before and after HBeAg seroconversion. All samples were taken in July or January of each year; thus, the preseroconversion sample would be expected to be on average 3 months prior to seroconversion (although the minimum time from seroconversion would be 1 day and the maximum 6 months) and the post-seroconversion sample would be expected to be taken on average 3 months after seroconversion (with a range of 1 day to 6 months, as above). Overall, there was a significant decrease in viral load from pre-to post-HBeAg seroconversion; whilst this decrease was significant in both subgroups, it was significantly greater in the group that did not have BCP double mutations (p=0.03, MannWhitney U test). As a result, whilst viral loads were significantly lower prior to HBeAg seroconversion in those with BCP double mutations than those without these mutations (P=0.01), the differences between the two groups were no longer significant after loss of HBeAg (P=0.27) (Fig. 2) . This suggests that, whilst BCP double mutations are associated with lower viral loads in HBeAg positive individuals, they have no effect on the viral loads of HBeAg negative individuals.
Association of BCP double mutations and viral loads before and after evolution of BCP double mutations in individuals without HBeAg or anti-HBe seroconversion
Because evolution of the BCP sequence was observed only in a few individuals, the number of individuals with samples available for analysis is too small to reach any reliable conclusions. However, it is clear that all viral loads decline after evolution of the BCP sequence from wild type to double mutations in individuals who remained HBeAg positive after the mutations were detected. However, viral loads may decline or increase after evolution of BCP mutations in individuals who remained HBeAg negative (Table 4) .
These results also suggest that BCP double mutations have no effect on viral loads in anti-HBe positive individuals but determination of their effect in HBeAg positive individuals requires further study.
Discussion
The principal finding of this study is that Reports of the association of BCP double mutations with virus replication have reached conflicting conclusions: increased virus replication [2, 7, 8] , no effect on virus replication [9] [10] [11] [12] 15, 24] or reduced virus replication [13] , and it is not clear which conclusion is reliable. Most of these studies are based on transfecting HBV DNA into cells in culture but virus replication in vitro differs from that in vivo, where it is influenced by the interaction of virus with the complex host immune system. The effect of BCP double mutations on virus replication in vitro may not be representative of the situation in vivo [25] . Although other studies are based on clinical samples, they all involve crosssectional analysis and viral loads may fluctuate over time [19] . In addition, seroconversion from HBeAg to anti-HBe, either spontaneous or after antiviral therapy, usually indicates lower viral loads. This decline may occur up to one year before HBeAg seroconversion [18] . One measurement, or measurements made close to seroconversion of HBeAg, may not be ideal for evaluating the effect of BCP double mutations on viral loads. This study included not only a cross-sectional analysis but also a long-term longitudinal analysis.
Therefore, the results are more reliable than previous studies.
The natural course of chronic HBV infection can be divided into four phases based on the virus-host interaction: immune tolerance, immunoreactive, low or non-replication, and reactivation. Virus replication proceeds at very high levels in immune tolerance phase, while HBV DNA levels fluctuate, but decreases progressively in the second, immunoreactive phase. HBeAg remains positive until clearance by the immune system at the end of the second phase. The third phase is characterised by undetectable HBeAg and anti-HBe positivity, with undetectable or low levels of HBV DNA [26] . It has been suggested that BCP double mutations may be selected through CTL escape when immune tolerance is lost and HBeAg concentrations are falling [27] . It may be postulated that, It has been suggested that BCP double mutations are associated with the development of HCC [28] [29] [30] [31] [32] [33] and this finding has been confirmed recently by our prospective cohort study [20] . However, the mechanisms of oncogenesis remain obscure. Although we hypothesized originally that BCP double mutations result in an increase in the levels of replicative intermediates and, consequently, of integration events [29] , the results of this study do not support this hypothesis and suggest that the association of BCP double mutations with the development of HCC is not attributable to increased viral DNA replication. In addition, it has been postulated that fulminant liver failure may be the result of increased virus replication resulting from the BCP mutations, which may upregulate pregenomic RNA, with concurrent down-regulation of precore RNA synthesis [15] . Again, our results do not support this postulate.
The association of other combinations of mutations, such as the triple core promoter mutations 1753/1762/1764, and viral loads remain uncertain. Huang et al. [34] suggested that these triple mutations are associated with lower HBV viral loads but others claim that they increase viral loads [14, 15] . We found there is no correlation of this combination of mutations with viral loads. Although mutations at nt 1766 and 1768 have been suggested to be associated with increased virus replication [14, 15] , these mutations are rare in our cohort (3 in 190 at nt 1766 and none in 190 at nt 1768). Mutations at nucleotide 1809-1817 may be associated with lower HBV viral loads [34] but this is not clear from the present study. A report from Hong Kong show that the major precore stop mutation is associated with lower viral loads [8] while there was no correlation between the presence of the mutation and HBV DNA levels in a Korean study [12] . The data presented here support the latter conclusion. 
